DaVita (NYSE:DVA) Posts Earnings Results, Beats Estimates By $0.54 EPS

DaVita (NYSE:DVA) posted its earnings results on Tuesday. The company reported $2.87 earnings per share for the quarter, topping analysts’ consensus estimates of $2.33 by $0.54, Zacks reports. The business had revenue of $3.42 billion for the quarter, compared to analyst estimates of $3.36 billion. DaVita had a negative return on equity of 413.18% and a net margin of 5.47%. DaVita updated its FY 2026 guidance to 14.100-15.200 EPS.

Here are the key takeaways from DaVita’s conference call:

• DaVita raised and narrowed its 2026 guidance — adjusted operating income to $2.15B–$2.25B and adjusted EPS to $14.10–$15.20 — attributing the increase mainly to higher volume and lower patient-care costs.
• Treatment volume guidance was lifted to +25–50 bps (≈+50–75 bps normalized treatments per day) driven by better-than-forecast mortality and patient transfers from Fresenius clinic closures.
• Q1 results beat expectations with adjusted operating income of $482M, adjusted EPS of $2.87, and free cash flow of $140M; the company repurchased ~5M shares and ended the quarter with leverage at 3.34x EBITDA.
• Management is investing in data, a proprietary EMR, and AI applications (e.g., Schedule Hub) to boost productivity and clinical outcomes, but benefits are early and contributed to a ~13% increase in G&A versus prior year.
• ACA open-enrollment is trending slightly more favorable than the prior ~$40M headwind estimate, but a shift toward lower-tier bronze plans could raise patient out-of-pocket costs and modestly pressure revenue per treatment.

DaVita Stock Up 1.9%

Shares of DVA traded up $2.90 during trading hours on Tuesday, hitting $156.98. 1,992,540 shares of the company were exchanged, compared to its average volume of 984,691. The company has a market cap of $10.49 billion, a price-to-earnings ratio of 15.84, a P/E/G ratio of 0.53 and a beta of 0.84. DaVita has a fifty-two week low of $101.00 and a fifty-two week high of $159.42. The firm’s fifty day moving average is $151.18 and its 200 day moving average is $131.51.

Institutional Trading of DaVita

Large investors have recently modified their holdings of the stock. Canada Pension Plan Investment Board acquired a new stake in shares of DaVita during the 2nd quarter worth $43,000. Caitlin John LLC acquired a new stake in shares of DaVita during the 4th quarter worth approximately $34,000. iSAM Funds UK Ltd acquired a new stake in shares of DaVita during the 3rd quarter worth approximately $46,000. Kestra Advisory Services LLC acquired a new stake in shares of DaVita during the 4th quarter worth approximately $45,000. Finally, AlphaCentric Advisors LLC acquired a new stake in shares of DaVita during the 4th quarter worth approximately $50,000. 90.12% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the company. Zacks Research lowered DaVita from a “strong-buy” rating to a “hold” rating in a report on Monday, April 6th. Truist Financial set a $158.00 price target on shares of DaVita in a research note on Thursday, February 5th. TD Cowen reiterated a “hold” rating on shares of DaVita in a research note on Tuesday, February 3rd. Wall Street Zen upgraded shares of DaVita from a “hold” rating to a “buy” rating in a research note on Saturday, February 21st. Finally, UBS Group upped their price objective on DaVita from $186.00 to $190.00 and gave the company a “buy” rating in a report on Wednesday, February 4th. One research analyst has rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $155.80.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.